- DNA Script recently announced that it has completed a Series C financing by raising $ 200 million in new capital. These are the details.
DNA Script – a pioneer in enzymatic DNA synthesis (EDS) for on-demand DNA printing – recently announced that it has completed a Series C funding by raising $ 200 million in new capital. And with this latest funding, DNA Script has raised $ 315 million since the company was founded in 2014.
Accounts and funds advised by T. Rowe Price Associates and Baillie Gifford participated in the second tranche of Series C, along with Healthcor Management, eureKARE and Irving Investors. They joined Coatue Management, Catalio Capital Management, Fidelity Management & Research Company LLC, Columbia Threadneedle Investments, Casdin Capital and other investors who participated in the first close.
The proceeds of this funding will be used to advance the SYNTAX platform, DNA Script’s first commercial product powered by its proprietary EDS technology. And SYNTAX enables scientists to quickly print synthetic nucleic acids for genomics and molecular biology applications from the comfort of their labs. Print-on-demand allows labs to iterate without waiting days or weeks to receive their genetic material from third-party service providers.
“We are delighted to partner with this group of world-class investors, including new entrants Baillie Gifford and T. Rowe Price, who collectively share our vision to increase access to oligos manufacturing to accelerate the bio-revolution. SYNTAX is the first step towards creating a new paradigm for DNA and RNA synthesis. With the support of our investors, we look forward to continuing to advance this new paradigm to solve some of our greatest challenges and advance human health. “
– Co-founder and CEO of DNA Script, Thomas Ybert